<DOC>
	<DOCNO>NCT00225082</DOCNO>
	<brief_summary>HIV infect subject receive antiretroviral treatment great 6 year evaluate clinical lipoatrophy mitochondrial function switch nucleoside analogue stavudine ( d4T ) tenofovir treatment 4 . Hypothesis : Tenofovir therapy increase peripheral fat content assess DEXA mitochondrial function 48 week .</brief_summary>
	<brief_title>SNAP : Switching Nucleoside Analogues Protocol - Lipoatrophy Mitochondrial Function</brief_title>
	<detailed_description>HIV infect subject receive antiretroviral treatment ( lopinavir/ritonavir , stavudine , lamivudine ) great 6 year Abbott M97-720 protocol evaluate clinical lipoatrophy mitochondrial function prior switch nucleoside analogue stavudine ( d4T ) tenofovir 48 week tenofovir treatment . Subjects without lipoatrophy eligible study . Adipose tissue biopsy measure mitochondrial function , metabolic laboratory test , DAXA scan clinical evaluation lipodystrophy perform Entry 48 week tenofovir treatment .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<criteria>HIV infection Receiving Kaletra , stavudine , lamivudine great 6 year ( Abbott M97720 study ) Planning switch stavudine tenofovir Will continue receive stavudine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Lipoatrophy</keyword>
	<keyword>Mitochondrial function</keyword>
	<keyword>Nucleoside analogue switch</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>